Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on July 30, 2021, regarding events effective August 1, 2021. The filing discloses executive promotions and the execution of new employment agreements for two senior officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The Board of Directors approved two executive promotions effective August 1, 2021:
- Jason A. Okazaki: Promoted to Chief Operating Officer (COO) while retaining duties as Chief Legal and Business Officer. His new role includes oversight of operations, investor outreach, IT, facilities, and general administrative functions.
- Michael P. Samar: Promoted to Chief Financial Officer (CFO), formalizing his role as principal financial and accounting officer which he had performed since June 2021.
Compensation Arrangements and Outlook
New employment agreements were executed for both executives with the following terms:
- Jason A. Okazaki (COO):
- Base Salary: $540,000 annually.
- Target Bonus: 55% of base salary.
- Change of Control Severance (within 12 months): 15 months' base salary, full target bonus, immediate equity vesting, and 15 months of COBRA premium reimbursement.
- Michael P. Samar (CFO):
- Base Salary: $400,000 annually.
- Target Bonus: 40% of base salary.
- Change of Control Severance (within 12 months): 12 months' base salary, full target bonus, immediate equity vesting, and 12 months of COBRA premium reimbursement.
- Standard Termination Severance (outside change of control): 12 months' base salary and 12 months of COBRA premium reimbursement.
Both executives' 2021 performance bonuses will be prorated based on their prior and new target percentages for the respective periods of the year.
Investor Verification Checklist
- Verify the full text of the Amended Employment Agreement for Jason A. Okazaki and the Employment Agreement for Michael P. Samar in the upcoming Form 10-Q for the period ended September 30, 2021.
- Review the definitive proxy statement on Schedule 14A filed April 7, 2021, for details on Mr. Okazaki's prior employment terms.
- Confirm the specific performance goals tied to the target bonus percentages for both executives.
- Monitor future filings for any changes to the executive team structure or additional compensation adjustments.